Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-30
DOI
10.3389/fimmu.2020.586907
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
- (2020) Hugo Arasanz et al. Cancers
- The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
- (2020) Joji Nagasaki et al. Blood Advances
- The first-week proliferative response of peripheral blood PD-1+CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
- (2019) Kyung Hwan Kim et al. CLINICAL CANCER RESEARCH
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
- (2019) Ana Bocanegra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
- (2019) Miren Zuazo et al. EMBO Molecular Medicine
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade
- (2019) Rohit R. Jadhav et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MHC-II neoantigens shape tumour immunity and response to immunotherapy
- (2019) Elise Alspach et al. NATURE
- CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities
- (2019) Tomasz Ahrends et al. Nature Communications
- CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
- (2019) Hiroshi Kagamu et al. Cancer Immunology Research
- Non-conventional Inhibitory CD4 + Foxp3 − PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
- (2018) Roberta Zappasodi et al. CANCER CELL
- Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
- (2018) Tao Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
- (2018) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Evolutionary Pressure against MHC Class II Binding Cancer Mutations
- (2018) Rachel Marty et al. CELL
- Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
- (2018) Nataly Manjarrez-Orduño et al. Frontiers in Immunology
- Hyperprogressive disease: recognizing a novel pattern to improve patient management
- (2018) Stéphane Champiat et al. Nature Reviews Clinical Oncology
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma
- (2017) Yoshiko Takeuchi et al. INTERNATIONAL IMMUNOLOGY
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- P3.02c-058 In-Depth Molecular Characterization of T Cell Clonal Expansion Induced by Anti-PD1 Therapy in NSCLC
- (2017) Sope Olugbile et al. Journal of Thoracic Oncology
- MA14.02 Evaluation of PD1/PDL1 Expression on Peripheral Blood Cells Subpopulations in Patients with Non-Small Cell Lung Cancer
- (2017) Oscar Arrieta et al. Journal of Thoracic Oncology
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an In Situ Inflammatory Immune Response
- (2016) Kristina Berg Lorvik et al. CANCER RESEARCH
- CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
- (2016) T. Ahrends et al. CANCER RESEARCH
- Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen
- (2016) Elena Shklovskaya et al. IMMUNOLOGY AND CELL BIOLOGY
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
- (2016) K. E. Pauken et al. SCIENCE
- T Cell Help Amplifies Innate Signals in CD8 + DCs for Optimal CD8 + T Cell Priming
- (2016) Marie Greyer et al. Cell Reports
- Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
- (2016) Sarah Knocke et al. Cell Reports
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
- (2016) B. Homet Moreno et al. Cancer Immunology Research
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
- (2015) Koen van de Ven et al. Immunotherapy
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells
- (2014) S. B. J. Wong et al. JOURNAL OF IMMUNOLOGY
- The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells
- (2014) Alessio Lanna et al. NATURE IMMUNOLOGY
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- The who's who of T-cell differentiation: Human memory T-cell subsets
- (2013) Yolanda D. Mahnke et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CD4+T Cells: Differentiation and Functions
- (2012) Rishi Vishal Luckheeram et al. Clinical & Developmental Immunology
- Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors
- (2012) T. M. Strutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD4+ memory T cell survival
- (2011) Justin J Taylor et al. CURRENT OPINION IN IMMUNOLOGY
- PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells
- (2011) Katarzyna Karwacz et al. EMBO Molecular Medicine
- CD8+ T Cells: Foot Soldiers of the Immune System
- (2011) Nu Zhang et al. IMMUNITY
- CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input
- (2011) Y. Kumamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Deciphering the role of Th17 cells in human disease
- (2011) Cailin Moira Wilke et al. TRENDS IN IMMUNOLOGY
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
- (2010) R. Bos et al. CANCER RESEARCH
- Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer
- (2010) Yan Zhang et al. Cellular & Molecular Immunology
- Regulation of CD4+ T-cell contraction during pathogen challenge
- (2010) K. Kai McKinstry et al. IMMUNOLOGICAL REVIEWS
- “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy
- (2010) Federico Garrido et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD4+ T Cells Elicit Host Immune Responses to MHC Class II- Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells
- (2010) Y. C. Nesbeth et al. JOURNAL OF IMMUNOLOGY
- Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
- (2009) I. Kryczek et al. BLOOD
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- (2009) Natalia Martin-Orozco et al. IMMUNITY
- Tumor-specific Th17-polarized cells eradicate large established melanoma
- (2008) P. Muranski et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started